Report: FDA hearing to discuss biosimilar regulations

WASHINGTON The Food and Drug Administration is looking for input on regulations concerning knock-off versions of biotech drugs, according to published reports.

 

The Hill, a newspaper in Washington, reported Monday that the FDA would have a hearing on Nov. 2 and 3 concerning follow-on biologics, based on a draft document distributed to healthcare lobbyists.

 

 

According to the report, the hearing would focus on such issues as interchangeability and definitions of such terms as “biological product.”

 

Login or Register to post a comment.